EAST END GROUP, LLC

Lobbying for GLAXOSMITHKLINE · Biotechnology pharmaceutical product discovery and development.

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2025 · District of Columbia · House · Senate · $30,000.00 income · posted Jul 17, 2025

Lobbying activity 1

Health Issues

General health care coverage and reimbursement for prescription drugs; drug pricing reform; and the Food and Drug Administration legislative and regulatory issues. Legislatives issues related to pandemic preparedness and response.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.